ArticleCureus2026
Use of Liquid Platelet-Rich Fibrin (Liquid PRF) as a New, Effective Regenerative Treatment for Steroid-Induced Subcutaneous and Dermal Atrophy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous and dermal atrophy are known complications of corticosteroid injections. Due to aesthetic and/or functional concerns, such as fat loss, visible depressions, skin thinning, and discoloration of the affected area, an effective treatment modality for reconstructing the area remains needed. Considering the regenerative properties of platelet-rich fibrin (PRF), its potential in soft tissue repair, and its efficacy in aesthetics, we used this natural autologous biomaterial to treat steroid-induced dermal and subcutaneous atrophy in our patient. A 35-year-old woman developed a well-defined atrophic area measuring approximately 3 × 7 cm² in the scapular region following a triamcinolone injection for shoulder pain. The area was characterized by a pronounced depression with irregular indented borders, along with dermal thinning and dyspigmentation. Treatment included three sessions of liquid PRF injections at monthly intervals. Each PRF injection session resulted in progressive improvement in the depth and quality of the atrophic area. One month after the third session and at six-month follow-up, significant improvement with marked restoration was observed in subcutaneous tissue volume, skin texture, depigmentation, and overall aesthetic outcomes based on subjective clinical assessment. No adverse effects were observed during treatment and follow-ups. Liquid PRF may represent a promising regenerative treatment for steroid-induced subcutaneous and dermal atrophy, warranting further controlled studies. Its potential to improve the thickness, volume, texture, and quality of both the dermal and subcutaneous fat layers may support the role of PRF as a therapeutic option for soft tissue restoration in dermatology and aesthetic medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.